EU-funded researchers develop new therapeutic strategy for atherosclerosis

NewsGuard 100/100 Score

Atherosclerosis is a common, potentially serious condition caused by a build-up of fatty material in the lining of the artery walls. It can lead to coronary artery disease, stroke or kidney problems, and existing treatments tend to be only short-term fixes.

In response to this public health challenge, EU-funded project THE GRAIL developed a new therapeutic strategy using a soft, compliant and intelligent ‘scaffold’ made of bioactive material to trigger the regeneration of diseased areas of blood vessels. This novel medical device could soon undergo the first clinical trials in humans.

The scaffold is made of biomimetic protein – which mimics existing proteins in the body – and is known as a synthesized intimal layer. The material is bio-resorbable, meaning it dissolves into the body once healthy arterial tissue has been restored. It should provide a more effective and longer-lasting solution than the therapeutic options currently available to atherosclerosis patients.

As the primary cause of cardiovascular disease, atherosclerosis has been the focus of considerable research leading to rather effective treatments. But these treatments have a major shortcoming: they are mostly short-term solutions, failing to restore vessel integrity in the long term."

Project coordinator Davide De Lucrezia of Explora Biotech in Italy

Effective, long-term treatment

Currently, patients diagnosed with atherosclerosis are typically treated with one of two methods: bypass surgery, in which blood flow is redirected to divert it around the diseased artery; or angioplasty, in which a balloon catheter is inserted and inflated to enlarge the artery walls.

However, many patients have to return to hospital within a few years as scarring from the surgery, recurring plaque build-up and other complications cause the treated blood vessels to start narrowing again.

The treatment developed by THE GRAIL researchers overcomes these issues. Instead of bypassing or artificially inflating diseased arteries, the team’s solution involved using the thin tube of a catheter, a minimally invasive technique, to insert the synthesized intimal layer into the diseased blood vessel.

Made of biopolymers based on elastine-like proteins, the soft scaffold includes bioactive molecules that are capable of recruiting the patient’s own endothelial cells. These cells, which line the interior surface of blood vessels, support regeneration from within the diseased and stiffened area of the artery.

A dedicated spin-off

We demonstrated the scaffold’s full biocompatibility in vitro and safety in vivo, and preliminary results on efficacy are extremely encouraging. Thanks to five years of EU support, we were able to progress THE GRAIL project from a simple sketch on a paper to a working prototype, paving the way for the commercial exploitation of the results."

Davide De Lucrezia

Three SME partners in THE GRAIL have set up a dedicated spin-off company that owns the intellectual property generated in the project and will engage with larger companies capable of supporting sales. The consortium has also sought to exploit by-products of the research, for instance, testing a new technique for peripheral vascular bypass surgery.

Meanwhile, expertise gained in the project has allowed Explora to offer advanced in-vivo models for safety and efficacy testing of advanced medical devices, making the company one of the leading SMEs in Europe in the field of advanced therapy medicinal product testing.

The project partners are negotiating investment from venture capital firms to develop the technology, potentially leading to the first clinical trials in human patients. If successful, THE GRAIL’s synthesized intimal layer could be used in surgery within a few years, addressing a critical need for effective, long-term treatment for atherosclerosis patients.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Unraveling the complexities of muscle repair in diabetes: A call for targeted research and therapies